There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

T he annual meeting of the American Society of Clinical Oncology is the most visible showcase for new cancer drug data. Join ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...